A Cancer and Leukemia Group B Phase II Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma (CALGB 80603)

BACKGROUND. The Cancer and Leukemia Group B (CALGB) conducted a phase II study evaluating sunitinib in patients with progressive metastatic pancreas adenocarcinoma following prior gemcitabine-based therapy (trial CALGB 80603; ClinicalTrials.gov identifier, NCT00397787). The primary endpoint was to d...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: O'Reilly, Eileen M., Niedzwiecki, Donna, Hall, Margaret, Hollis, Donna, Bekaii-Saab, Tanios, Pluard, Timothy, Douglas, Kathe, Abou-Alfa, Ghassan K., Kindler, Hedy L., Schilsky, Richard L., Goldberg, Richard M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: AlphaMed Press 2010
Soggetti:
Gastrointestinal Cancer
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3227926/
https://ncbi.nlm.nih.gov/pubmed/21148613
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0152
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi